|

Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis

RECRUITINGN/ASponsored by Azienda Ospedaliero, Universitaria Ospedali Riuniti
Actively Recruiting
PhaseN/A
SponsorAzienda Ospedaliero, Universitaria Ospedali Riuniti
Started2018-01-01
Est. completion2022-05-05
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06071156

Summary

To determine the utility of serial cardiac magnetic resonance (CMR) imaging for guidance of therapy management in patients treated with anakinra due to recurrent pericarditis (RP), compared with c-reactive protein (CRP) assay alone.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Adult patients treated with anakinra 100 mg/die if ≥ 18 years old, and
* Pediatric patients treated with anakinra 2 mg/kg/die if \< 18 years old
* Pediatric and adult patients treated with anakinra due to corticosteroid-dependent or not responsive to colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) recurrent pericarditis

Exclusion Criteria:

* Ongoing infection (proved within serology)
* Refuse to participate in the trial

Conditions2

Heart DiseaseRecurrent Pericarditis

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.